GSK690693, a small molecule ATP-competitive pan inhibitor of the pro-survival kinase Akt, preclinically tested in osteosarcoma and ALL xenografts, is now in phase I of clinical trials in sarcomas, neuroblastoma, non-glioblastoma brain tumors and lymphoma [27, 28]. Here, AKT1 is linked to brain neoplasm.